Federal grants to Myofinity Biosciences Inc
Myofinity Biosciences Inc in Woodbridge, Connecticut received $2.2 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Arthritis, Musculoskeletal and Skin Diseases Research, with $2.0 million. In fiscal 2025 it was awarded $587,105.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$2.2 million
- Awards4
- Awarded in FY 2025$587,105
- Largest award$1.7 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | -$24,811 |
| FY 2022 | 1 | $259,487 |
| FY 2023 | 3 | $571,187 |
| FY 2024 | 1 | $811,438 |
| FY 2025 | 1 | $587,105 |
Programs that fund Myofinity Biosciences Inc
| Program | Awards | Amount |
|---|---|---|
| Arthritis, Musculoskeletal and Skin Diseases Research | 3 | $2.0 million |
| Human Genome Research | 1 | $250,000 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $2.2 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Membrane repair as a therapeutic intervention for treating becker muscular dystrophy - project abstract the goal of this combined phase i/II sbir project is to accomplish key milestones in commercializing a protein therapeutic for becker muscular dystrophy (BMD) that will enhance the repair capacity | Arthritis, Musculoskeletal and Skin Diseases Research | September 20, 2023 | $1.7 million |
| Translational development of recombinant protein therapeutic for LGMD2B - project abstract this phase i sttr project will accomplish key milestones in commercializing a protein therapeutic for dysferlinopathies that will enhance the repair capacity of muscle cell membranes compromised by mutations i | Arthritis, Musculoskeletal and Skin Diseases Research | July 15, 2022 | $259,487 |
| Translational development of novel crispr approach to treat genomic duplications - project abstract the goal of this phase i sttr project is to accomplish key milestones in commercializing a novel SACAS9 nickase-based system (CRD-002) to treat dystrophinopathies in order to restore the production of | Human Genome Research | July 25, 2023 | $250,000 |
| Translational development of novel crispr approach to treat genomic duplications - project abstract the goal of this phase i sttr project is to accomplish key milestones in commercializing a novel SACAS9 nickase-based system (CRD-002) to treat dystrophinopathies in order to restore the production of | Arthritis, Musculoskeletal and Skin Diseases Research | July 25, 2023 | $25,651 |
Questions people ask
How much federal grant money does Myofinity Biosciences Inc get?
$2.2 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Myofinity Biosciences Inc the most?
The Department of Health and Human Services, with $2.2 million in 4 awards.
What is Myofinity Biosciences Inc's largest federal grant?
$1.7 million under Arthritis, Musculoskeletal and Skin Diseases Research, with its first action in the period on September 20, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Myofinity Biosciences Inc?
Its largest are Arthritis, Musculoskeletal and Skin Diseases Research and Human Genome Research.
Other grant recipients in Woodbridge
Largest federal grant recipients in Connecticut · Federal grants in Connecticut